The Allure Of High-Hanging Fruit: Why VCs and Biotech Execs See Value In Difficult Drug Targets
By
Shirley Haley / Email the Author / START-UP December 2010, Vol. 15, No. 11
Feature Articles / Word Count: 4587 / Article # 2010900247
Executive Summary
An agile and energetic cohort of biotech platform companies plans to capture Big Pharma's imagination--and its pocketbook--by going after intractable drug targets that have long eluded the industry, and they're doing it on a shoestring budget.
$125.00
Buy Now
For $125.00, purchase this 4587-word article and receive immediate online access. 100% Satisfaction Guarantee.
Already a Subscriber?
Log in for complete access.
Log In
Questions?
Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.